$$R_3$$
 NH_2 CO_2H

$$Q = \qquad = \qquad \text{or} \qquad \stackrel{R_1^1}{}_{Q}$$

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl be substituted by alkoxy or one or more halo.

Please insert therefor:

$$H_3C$$
 H_3C
 Q
 CO_2H

$$Q =$$
 or R_{1}^{1}

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 4, third paragraph (lines 11-18), to page 5, first paragraph (lines 1-4), please delete (replace):

In an embodiment represented by Formula I, the invention relates to:

$$R_3^3$$
 NH_2
 R_1 CO_2H
 R_1 R_2 R_2 R_2 R_2 R_2 R_3 R_4 R_4 R_4 R_4 R_5 R_5 R_6 R_7 R_8 R_8 R_8 R_9 R_9

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl be substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula I, the invention relates to:

$$H_3C$$
 H
 R^3
 CO_2H
 R^2
 R^2

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 5, fourth paragraph (lines 12-23), please delete (replace):

In an embodiment represented by Formula III, the invention relates to:

$$H_3C$$
 NH
 R^3
 NH_2
 CO_2H

Ш

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl **be** substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula III, the invention relates to:

$$H_3C$$
 NH
 R^3
 CO_2H

Ш

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 6, second paragraph (lines 7-17), please delete (replace):

In an embodiment represented by Formula V, the invention relates to:

$$H_3C$$
 R_1
 R_2
 CO_2H

ν

or a pharmaceutically acceptable salt thereof, wherein:

3366/1US

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl **be** substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula V, the invention relates to:

$$H_3C$$
 H
 R^3
 CO_2H

V

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 17, last paragraph (line 30), to page 18, first paragraph (lines 1-10), please delete (replace):

In an embodiment represented by Formula I, the invention relates to:

$$H_3C$$
 H
 R^3
 CO_2H
 R^2

or a pharmaceutically acceptable salt thereof, wherein:

 R^{1} is selected from the group consisting of hydrogen, halo, C_{1} - C_{5} alkyl and C_{1} - C_{5} alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R³ is C₁-C₅ alkyl or C₁-C₅ alkyl be substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula I, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 CO_2H
 R^2
 R^2

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 21, ninth paragraph (lines 19-27), to page 22, first paragraph (lines 1-3), please delete (replace):

In an embodiment represented by Formula III, the invention relates to:

$$H_3C$$
 R^3
 NH_2
 CO_2H

Ш

or a pharmaceutically acceptable salt thereof, wherein:

 R^1 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^2 is selected from the group consisting of hydrogen, halo, C_1 - C_5 alkyl and C_1 - C_5 alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl be substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula III, the invention relates to:

$$R_3$$
C R_1 R_2 R_2 R_2 R_2 R_2 R_2 R_2 R_2 R_3 R_4 R_4 R_4 R_4 R_4 R_5 R_5 R_6 R_7 R_8 R_7 R_8 R_8 R_8 R_9 R_9

III

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl substituted by alkoxy or one or more halo.

Page 25, fourth paragraph (lines 7-18), please delete (replace):

In an embodiment represented by Formula V, the invention relates to:

$$H_3C$$
 H_3C
 R^3
 NH_2
 CO_2H

V

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

R² is selected from the group consisting of hydrogen, halo, C₁-C₅ alkyl and C₁-C₅ alkyl substituted by alkoxy or one or more halo;

 R^3 is C_1 - C_5 alkyl or C_1 - C_5 alkyl be substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula V, the invention relates to: